Work

Pharmacokinetics, efficacy, and safety of a novel aripiprazole microsphere-based long-acting injectable formulation for schizophrenia: A multicenter, randomized controlled trial

Year: 2025

Type: article

Study design: Clinical Trial

Abstract: • A microsphere-based formulation of aripiprazole (MS350) was investigated • MS350 was bioequivalence to microcrystalline formulation with more stable plasma levels • MS350 had fewer adverse events, demonstrating a better safety profile

Source: Journal of Pharmaceutical Analysis

DOI: 10.1016/j.jpha.2025.101350

Authors: An-Ning Li, Sheng-Chun Jin, De-Wei Shang, Jian-Xiong Guo, Hua-Li Lin, Ming Zhang, Bo Wei, Feng Wan, Yun-Long Tan, Li-Li Wang, Jian-Chu Zhou, Ping Liu, Lian-Lian Fan, Ju-Shui Sun, Bin Chen, Yimin Cui, Gang Wang

Institutions: Capital Medical University, Beijing Anding Hospital, Guangzhou Medical University, Xian Mental Health Center, Shenzhen KangNing Hospital, Beijing HuiLongGuan Hospital, Tianjin Anding Hospital, Third People's Hospital of Huzhou, Peking University First Hospital

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,950

Funders: National Science and Technology Major Project, National Major Science and Technology Projects of China

Award: G6363353051

OpenAlex ID: W4410615674

FWCI:

Cites: 4

Cited by:

Related to: 10